Literature DB >> 8099300

Rapid and sustained hematopoietic reconstitution by peripheral blood stem cell infusion alone following high-dose chemotherapy.

L Schwartzberg1, R Birch, R Blanco, F Wittlin, J Muscato, K Tauer, B Hazelton, W West.   

Abstract

We utilized mobilized peripheral blood stem cells (PBSC) as sole support for hematologic reconstitution following high-dose chemotherapy in 52 patients with advanced solid tumors and lymphoma. PBSC were collected by large scale leukapheresis after mobilization with chemotherapy. Each apheresis product was analysed for total nucleated cells, CFU-GM and CD34+ content. Disease-specific high-dose chemotherapy regimens were administered followed by thawed PBSC. Colony-stimulating factors were not administered. The median time to an absolute neutrophil count > 0.5 x 10(9)/l was 13 days (range 9-26 days) and median time to a sustained platelet count > 20 x 10(9)/l without transfusion support was 10 days (range 5-43 + days). There was no difference in time to recovery by dose-intensive regimen or underlying disease. The times to recover ANC and platelets both correlated significantly with increasing doses of PBSC as assayed by CD34+ cells and CFU-GM. All four patients with prolonged platelet recovery times received < 20 x 10(4) CFU-GM/kg, establishing this as a threshold value for PBSC infusion. There were no late transient or sustained graft failures. For 26 patients alive 1 year after infusion, the mean total leukocyte count is 6.3 x 10(9)/l, mean hematocrit 35.5% and mean platelet count 182 x 10(9)/l. Thirteen patients followed at least 24 months after PBSC infusion have essentially normal blood counts. Mobilized peripheral blood progenitors are an effective source of stem cells which afford rapid and complete hematopoietic engraftment after myelo-suppressive chemotherapy regimens. Engraftment appears sustained with no late failures.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1993        PMID: 8099300

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  8 in total

1.  Semi-mechanistic model for neutropenia after high dose of chemotherapy in breast cancer patients.

Authors:  Amelia Ramon-Lopez; Ricardo Nalda-Molina; Belen Valenzuela; Juan Jose Perez-Ruixo
Journal:  Pharm Res       Date:  2009-06-02       Impact factor: 4.200

Review 2.  Autologous peripheral blood stem cells: collection and processing.

Authors:  M Hansson; A Svensson; P Engervall
Journal:  Med Oncol       Date:  1996-06       Impact factor: 3.064

3.  Stem cell transplantation for metastatic breast cancer: analysis of tumor contamination.

Authors:  E A Stadtmauer; D E Tsai; C J Sickles; R Mick; S M Luger; D L Porter; P A Mangan; L M Schuchter; S J Schuster; E Y Loh; D A Magee; R A Sachs; M E Wall; J Moore; G P Buzby; E Zaleta; M Kamoun; L E Silberstein
Journal:  Med Oncol       Date:  1999-12       Impact factor: 3.064

4.  Autografting with blood progenitor cells: predictive value of preapheresis blood cell counts on progenitor cell harvest and correlation of the reinfused cell dose with hematopoietic reconstitution.

Authors:  N Schwella; W Siegert; J Beyer; O Rick; J Zingsem; R Eckstein; S Serke; D Huhn
Journal:  Ann Hematol       Date:  1995-11       Impact factor: 3.673

5.  Effect of rhG-CSF on the mobilization of CD38 and HLA-DR subfractions of CD34+ peripheral blood progenitor cells.

Authors:  M L Lozano; F Ortuño; F de Arriba; M C Rosillo; J Rivera; I Heras; V Vicente
Journal:  Ann Hematol       Date:  1995-09       Impact factor: 3.673

Review 6.  Clinical outcome of peripheral blood stem cell support.

Authors:  A Kessinger; J Armitage; P Bierman; M Bishop; S Joshi; E Reed; G Sharp; J Talmadge; J Vose
Journal:  Med Oncol       Date:  1994       Impact factor: 3.064

Review 7.  Autologous hematopoietic stem cell transplantation following high dose chemotherapy for non-rhabdomyosarcoma soft tissue sarcomas.

Authors:  Frank Peinemann; Lesley A Smith; Carmen Bartel
Journal:  Cochrane Database Syst Rev       Date:  2013-08-07

8.  Peripheral Blood Stem Cell Harvest HPC Count Is an Effective Surrogate Marker for CD34+ Cell Count in Allogeneic Stem Cell Transplant Setting.

Authors:  Aisha Jamal; Mohammad Tahir Khan; Sadia Parveen; Qurratulain Rizvi; Tasneem Farzana; Uzma Zaidi; Munira Borhany; Saima Siddiqui; Saqib Hussain Ansari; Tahir Sultan Shamsi
Journal:  Transl Oncol       Date:  2020-05-11       Impact factor: 4.243

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.